Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $24.00 at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price hoisted by investment analysts at UBS Group from $22.00 to $24.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 40.35% from the stock’s previous close.

TEVA has been the subject of several other reports. Jefferies Financial Group raised their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Piper Sandler reissued an “overweight” rating and issued a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Wednesday. Finally, Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.56.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $17.10 on Wednesday. The stock has a market capitalization of $19.37 billion, a P/E ratio of -41.71, a P/E/G ratio of 1.55 and a beta of 0.90. Teva Pharmaceutical Industries has a twelve month low of $7.95 and a twelve month high of $17.69. The company has a 50 day moving average of $16.53 and a 200-day moving average of $14.05. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The firm had revenue of $3.82 billion during the quarter, compared to the consensus estimate of $3.70 billion. As a group, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.32 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the sale, the director now owns 981,000 shares in the company, valued at approximately $16,706,430. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the sale, the director now owns 981,000 shares of the company’s stock, valued at approximately $16,706,430. The disclosure for this sale can be found here. In the last 90 days, insiders sold 549,719 shares of company stock worth $9,353,736. 0.55% of the stock is owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janney Montgomery Scott LLC raised its position in shares of Teva Pharmaceutical Industries by 13.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after buying an additional 164,614 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Teva Pharmaceutical Industries by 705.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock valued at $6,051,000 after buying an additional 507,568 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Teva Pharmaceutical Industries by 31.7% in the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after buying an additional 131,043 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock valued at $3,515,000 after buying an additional 102,261 shares in the last quarter. Finally, Gateway Investment Advisers LLC raised its position in shares of Teva Pharmaceutical Industries by 28.6% in the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock valued at $437,000 after buying an additional 9,312 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.